You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 17, 2025

Details for Patent: 7,645,460


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 7,645,460 protect, and when does it expire?

Patent 7,645,460 protects ATELVIA and is included in one NDA.

This patent has eighty-four patent family members in thirty-three countries.

Summary for Patent: 7,645,460
Title:Dosage forms of risedronate
Abstract:Oral dosage forms of a risedronate comprised of a safe and effective amount of a pharmaceutical composition comprising risedronate, a chelating agent, and, means for effecting delayed release of the risedronate and the chelating agent in the small intestine provide immediate release of the pharmaceutical composition to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between risedronate and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies.
Inventor(s): Dansereau; Richard John (Cincinnati, OH), Burgio, Jr.; David Ernest (Liberty Township, OH)
Assignee: The Procter & Gamble Company (Cincinnati, OH)
Application Number:11/286,875
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,645,460
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Delivery; Use;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 7,645,460

Introduction

Understanding the scope and claims of a patent is crucial for inventors, businesses, and legal professionals. This article will delve into the details of United States Patent 7,645,460, exploring its claims, scope, and the broader patent landscape.

Patent Overview

United States Patent 7,645,460, hereafter referred to as the '460 patent, is a utility patent that was granted to Warner Chilcott Company, LLC. To analyze this patent, we need to look at its claims, the technology it covers, and any relevant legal and technical contexts.

Claims Analysis

Claim Structure

Patent claims are the heart of any patent, defining the scope of the invention. The '460 patent includes multiple claims, each of which outlines a specific aspect of the invention. For instance, claim 20 of the '460 patent was a subject of litigation in the case of Warner Chilcott Co., LLC v. Teva Pharms. USA, Inc.[2].

Claim 20

Claim 20 is particularly noteworthy as it was one of the claims that underwent significant scrutiny during the litigation. This claim would typically describe a specific embodiment or aspect of the invention, and its validity and scope would be critical in determining the patent's overall enforceability.

Scope of the Patent

Independent Claim Length and Count

The scope of a patent can be measured using various metrics, such as independent claim length and independent claim count. Research suggests that narrower claims at publication are associated with a higher probability of grant and a shorter examination process than broader claims[3].

Patent Maintenance Payments and Forward Citations

The scope of the '460 patent can also be inferred from its maintenance payments and forward citations. Patents with narrower claims tend to have higher maintenance payments and more forward citations, indicating their relevance and impact in the field[3].

Patent Landscape

Prior Art and Citation Data

To understand the '460 patent's place in the patent landscape, it is essential to look at prior art and citation data. Tools like the Common Citation Document (CCD) and the Patent Public Search tool provided by the USPTO can help in identifying prior art cited by various patent offices for the same invention[1].

Global Dossier

The Global Dossier service allows users to view the patent family for a specific application, including all related applications filed at participating IP Offices. This can provide insights into how the '460 patent is related to other patents globally[1].

Legal Context

Litigation History

The '460 patent has been involved in litigation, notably in the case against Teva Pharmaceuticals USA, Inc. This litigation highlighted the importance of claim 20 and other claims in determining the patent's validity and enforceability[2].

Court Rulings

Court rulings in such cases can significantly impact the scope and claims of a patent. For example, the court may find certain claims invalid or limit the scope of the patent based on evidence presented during the trial[5].

Technical Context

Cooperative Patent Classification (CPC)

The Cooperative Patent Classification (CPC) system can help in understanding the technical classification of the '460 patent. This system allows for more precise searching and categorization of patents, providing a clearer picture of the patent's technical scope[4].

International Patent Cooperation

The '460 patent, like many others, is part of an international patent cooperation framework. Databases such as PATENTSCOPE and the European Patent Office's esp@cenet provide access to international patent applications and granted patents, allowing for a global perspective on the patent's scope and claims[1][4].

Practical Implications

Conducting a Preliminary Search

For those interested in understanding the '460 patent or conducting a similar search, the USPTO provides several resources, including the Patent Public Search tool and the Patent and Trademark Resource Centers (PTRCs). These resources can help in conducting a preliminary search to identify prior art and understand the patent landscape[1][4].

Machine Translation and Sequence Listings

Tools like machine translation services provided by the European Patent Office and the Japan Patent Office can facilitate the search process by making foreign patents more accessible. Additionally, resources like the Publication Site for Issued and Published Sequences (PSIPS) can be useful for patents involving sequences and tables[1][4].

Key Takeaways

  • Claims Analysis: Understanding the specific claims, such as claim 20 of the '460 patent, is crucial for determining the patent's scope and enforceability.
  • Scope Metrics: Metrics like independent claim length and count can provide insights into the patent's breadth and validity.
  • Prior Art and Citation Data: Tools like the CCD and Global Dossier are essential for identifying prior art and understanding the patent's global context.
  • Legal and Technical Context: Litigation history and technical classifications using CPC can further clarify the patent's scope and claims.
  • Practical Resources: Utilizing resources like the Patent Public Search tool and PTRCs can aid in conducting thorough patent searches.

FAQs

Q: What is the significance of claim 20 in the '460 patent? A: Claim 20 was a subject of litigation and is crucial in defining the scope and enforceability of the '460 patent.

Q: How can one measure the scope of a patent like the '460 patent? A: Metrics such as independent claim length and count, as well as maintenance payments and forward citations, can be used to measure the scope of a patent.

Q: What tools are available for searching prior art related to the '460 patent? A: Tools like the Common Citation Document (CCD) and the Patent Public Search tool provided by the USPTO are available for searching prior art.

Q: How does the Global Dossier service help in understanding the '460 patent? A: The Global Dossier service allows users to view the patent family for a specific application, including all related applications filed at participating IP Offices.

Q: What resources are available for conducting a preliminary patent search? A: Resources include the Patent Public Search tool, Patent and Trademark Resource Centers (PTRCs), and training materials provided by the USPTO.

Sources

  1. USPTO - Search for patents: https://www.uspto.gov/patents/search
  2. Robins Kaplan - Warner Chilcott Co., LLC v. Teva Pharms. USA, Inc.: https://www.robinskaplan.com/newsroom/insights/warner-chilcott-co-v-teva-pharms-usa
  3. SSRN - Patent Claims and Patent Scope: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2844964
  4. Clemson University - Advanced Patent Searching: https://clemson.libguides.com/advanced_patent_searching
  5. Finnegan - CLOSED UNITED STATES DISTRICT COURT DISTRICT OF NEW: https://www.finnegan.com/a/web/101579/2015.03.04-211cv06936-Warner-v-Teva-Judgment-DI307.pdf

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 7,645,460

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
Apil ATELVIA risedronate sodium TABLET, DELAYED RELEASE;ORAL 022560-001 Oct 8, 2010 AB RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN ⤷  Try for Free
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 1 to 1 of 1 entries

International Family Members for US Patent 7,645,460

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Argentina 049022 ⤷  Try for Free
Argentina 098686 ⤷  Try for Free
Austria E475412 ⤷  Try for Free
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 3 of 3 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.